Phibro's CEO transition puts this insider sale in context

1 hour ago 3

Seena Hassouna, The Motley Fool

Sat, May 23, 2026 astatine 4:27 PM CDT 4 min read

Jack Bendheim, President and CEO of Phibro Animal Health Corporation (NASDAQ:PAHC), disclosed the indirect merchantability of 18,608 shares of Common Stock crossed aggregate open-market transactions from May 5, 2026 done May 7, 2026, arsenic reported successful the SEC Form 4 filing.

Transaction summary

Metric

Value

Shares sold (indirect)	18,608
Transaction value	$1.0 million
Post-transaction shares (direct)	16,840
Post-transaction shares (indirect)	56,152
Post-transaction worth (direct ownership)	~$727K

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($54.61); post-transaction worth based connected full reported shares multiplied by the last May 7, 2026 adjacent price, arsenic calculated successful SEC data.

Key questions

How worldly was the simplification successful indirect ownership from this sale?
This merchantability accounted for 24.89% of Jack Bendheim's indirect holdings, reducing his indirect presumption via BFI Co. LLC from 74,760 shares to 56,152 shares arsenic of May 7, 2026.
What trading program governed these transactions?
These income were executed nether a Rule 10b5-1 trading program adopted by BFI Co., LLC connected December 11, 2025
How bash these trades comparison to Bendheim's humanities activity?
Since January 2026, commercialized sizes person remained wrong the emblematic humanities scope for Bendheim, with the astir caller income reflecting a simplification successful capableness arsenic full reported holdings fell by 96.77% from 520,712 to 16,840 shares implicit the "recent" period.
Does Bendheim support a worldly ownership involvement aft this transaction?
Despite this disposition, Bendheim continues to person vulnerability done 16,840 straight held shares, 56,152 shares held indirectly, and a full of 449,485 Class A Common Stock shares (direct and indirect), which are convertible into Common Stock, preserving meaningful economical alignment.

Company overview

Metric

Value

Revenue (TTM)	$1.50 billion
Net income (TTM)	$95.23 million
Dividend yield	1.88%
1-year terms change	50.21%

* 1-year show calculated utilizing May 7th, 2026 arsenic the notation date.

Company snapshot

PAHC produces and markets carnal wellness products, nutritional specialties, vaccines, and mineral nutrition solutions for livestock, including poultry, swine, cattle, and aquaculture.
The institution generates gross chiefly done the merchantability of proprietary and generic pharmaceuticals, nutritional additives, and specialty ingredients to the commercialized carnal agriculture sector.
It serves integrated poultry, swine, and cattle producers, arsenic good arsenic carnal provender manufacturers, wholesalers, and distributors crossed the United States and planetary markets.

Read Entire Article